Table 3 Other Sensitivity Analyses for Propensity Score Matched Patients
Dabigatran vs Warfarin | Rivaroxaban vs Warfarin | Apixaban vs Warfarin | |
|---|---|---|---|
Censoring at 6 Months, HR (95% CI) | |||
Sample Size | N = 3691 vs N = 3691 | N = 8226 vs N = 8226 | N = 7607 vs N = 7607 |
Stroke/SE | 0.68 (0.37–1.23) | 0.90 (0.63–1.29) | 0.51 (0.33–0.79) |
Major bleeding | 1.10 (0.75–1.61) | 1.12 (0.91–1.39) | 0.59 (0.45–0.77) |
Intent-to-Treat, HR (95% CI) | |||
Sample Size | N = 3691 vs N = 3691 | N = 8226 vs N = 8226 | N = 7607 vs N = 7607 |
Stroke/SE | 0.76 (0.57–1.03) | 1.04 (0.86–1.26) | 0.63 (0.49–0.81) |
Major bleeding | 0.97 (0.80–1.19) | 1.01 (0.89–1.15) | 0.75 (0.64–0.88) |
Excluding Patients with Catheter Ablation or Cardioversion, HR (95% CI) | |||
Sample Size | N = 3298 vs N = 3298 | N = 7698 vs N = 7698 | N = 7034 vs N = 7034 |
Stroke/SE | 0.68 (0.43–1.07) | 0.83 (0.64–1.09) | 0.55 (0.39–0.77) |
Major bleeding | 1.05 (0.79–1.40) | 1.07 (0.91–1.27) | 0.65 (0.53–0.80) |